Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.75 |
| ▸ | HTR7 | P34969 | 6/20 | 0.75 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11446686 | 0.84 | HTR7 (0.64) | HTR1AHTR7 | |
| SCHEMBL11448262 | 0.81 | HTR1A (0.58) | HTR1AHTR7TSHRKMT2AGFER | |
| SCHEMBL6802419 | 0.81 | HTR7 (0.57) | HTR1AHTR7KDM4EALDH1A1 | |
| SCHEMBL6801275 | 0.81 | HTR1A (0.55) | HTR1AHTR7CACNA1GTSHRLMNA | |
| Hydrochloric Acid SCHEMBL11500448 | 0.81 | HTR1A (0.57) | HTR1AHTR7TSHRKMT2AGFER | |
| SCHEMBL6797005 | 0.81 | DRD2 (0.59) | HTR1AHTR7KDM4EALDH1A1 | |
| SCHEMBL3207003 | 0.80 | HTR1A (0.67) | HTR1AHTR7CACNA1G | |
| SCHEMBL11827948 | 0.80 | HTR2A (0.53) | HTR1AHTR7CACNA1GTSHRALDH1A1 | |
| SCHEMBL12946163 | 0.80 | HTR1A (0.58) | HTR1AHTR7CACNA1GKMT2ANPSR1 | |
| SCHEMBL8273954 | 0.80 | HTR7 (0.55) | HTR1AHTR7CACNA1GKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | HTR1A 848/4885HTR7 1045/4885CACNA1G 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.